Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Plasmablastic Lymphoma 1 Lymphomatoid Granulomatosis 1 Lymphoma, Primary Effusion 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell 1 Glioblastoma 1 Burkitt Lymphoma 1

Interventions

Temozolomide 41 Magnetic Resonance Spectroscopy 21 Radiotherapy 19 Specimen Handling 15 Radiation 12 Bevacizumab 11 Lomustine 9 pembrolizumab 6 fludarabine 5 Surgical Procedures, Operative 5 atezolizumab 4 Nivolumab 4 Ipilimumab 4 Cyclophosphamide 4 Carboplatin 4 Biopsy 4 cemiplimab 3 azeliragon 3 Immunoglobulin G 3 Disulfides 3 Aminolevulinic Acid 3 veliparib 2 trametinib 2 rocakinogene sifuplasmid 2 ribociclib 2 poly ICLC 2 pamiparib 2 olaparib 2 niraparib 2 lutetium Lu 177 dotatate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Glioblastoma × varlilumab × 90 days × Clear all

NCT03688178 2026-05-22

DERIVe

Duke University

Phase 2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡